I
InVivo Biosystems accelerates drug discovery for neurological, metabolic, and rare monogenic diseases through its premier proprietary platform, RapidGen™. By harnessing cutting-edge -omics data and multiplexed CRISPR technology, the RapidGen™ platform streamlines target identification and enables multimodal therapeutic screening with precision. With advanced in vivo wet lab capabilities, InVivo Biosystems delivers robust behavioral and molecular insights, driving innovation and fostering strategic partnerships to revolutionize preclinical research.
Investor insights
Funding rounds participated in
$3M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2011
Funding rounds raised
Total raised
$3M
from 2 investors over 1 rounds
I
InVivo Biosystems raised $3M on February 3, 2024
Investors: Rogue Venture Partners and + 2 Other investors